Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in iranian patients with erosive reflux esophagitis

Archives of Iranian Medicine

Volumn 13, Issue 5, 2010, Pages 406-412

  Zendehdel, Nader ^a   Biramijamal, Firouzeh ^a   Hossein Nezhad, Arash ^e   Zendehdel, Nasrin ^b   Sarie, Hamidreza ^c   Doughaiemoghaddam, Masoud ^c   Pourshams, Akram ^d  

^a NATIONAL INSTITUTE OF GENETIC ENGINEERING AND BIOTECHNOLOGY   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Fayazbakhsh Hospital   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clinical response; Cytochrome P450 2C19; Erosive reflux esophagitis; Genetic polymorphism; Omeprazole

Indexed keywords

CYTOCHROME P450 2C19; OMEPRAZOLE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; ESOPHAGOSCOPY; FEMALE; GENETIC POLYMORPHISM; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; REFLUX ESOPHAGITIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALLELES; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; ESOPHAGITIS, PEPTIC; ESOPHAGOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; GENOTYPE; HUMANS; IRAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OMEPRAZOLE; POLYMORPHISM, GENETIC; PROTON PUMP INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78149236972     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Malekzadeh R, Nasseri-Moghaddam S, Sotoudeh M. Gstroesophageal reflux disease: the new epidemic. Arch Iran Med. 2003; 6: 127-140.
2. Nouraie M, Radmard AR, Zaer-Rezaii H, Razjouyan H, Nasseri-Moghaddam S, Malekzadeh R. Hygiene could affect GERD prevalence independently: a population- based study in Tehran. Am J Gastroenterol. 2007; 102: 1353-1360.
3. Iwakiri K, Kawami N, Sano H, Tanaka Y, Umezawa M, Kotoyori M, et al. Mechanisms of excessive esophageal acid exposure in patients with reflux esophagitis. Dig Dis Sci. 2009; 54: 1686-1692.
4. Kulig M, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease-- an analysis based on the ProGERD initiative. Aliment Pharmacol Ther. 2003; 18: 767-776.
5. Mokrowiecka A, Jurek K, Pinkowski D, Malecka-Panas E. The comparison of Health-Related Quality of Life (HRQL) in patients with GERD, peptic ulcer disease, and ulcerative colitis. Adv Med Sci. 2006; 51: 142-147.
6. Boeckxstaens GE. Review article: the pathophysiology of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2007; 26: 149-160.
7. Castell DO, Murray JA, Tutuian R, Orlando RC, Arnold R. Review article: the pathophysiology of gastro-oesophageal reflux disease-oesophageal manifestations. Aliment Pharmacol Ther. 2004; 20 (suppl 9): 14-25.
8. Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006; 23 (suppl 2): 2-8.
9. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008; 64: 935-951.
10. Chaudhry AS, Kochhar R, Kohli KK. Genetic polymorphism of CYP2C19 and therapeutic response to proton pump inhibitors. Indian J Med Res. 2008; 127: 521-530.
11. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008; 392: 1093-1108.
12. Klotz U, Schw AB, M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol. 2004; 95: 2-8.
13. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994b; 269: 15419-15422.
14. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994a; 46: 594-598.
15. Zand N, Tajik N, Moghaddam AS, Milanian I. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol Physiol. 2007; 34: 102-105.
16. Egan LJ, Myhre GM, Mays DC, Dierkhising RA, Kammer PP, Murray JA. CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment Pharmacol Ther. 2003; 17: 1521-1528.
17. Ohkusa T, Maekawa, T, Arakawa T, Nakajima M, Fujimoto K, Hoshino E, et al. Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis. Aliment Pharmacol Ther. 2005; 21: 1331-1339.
18. Kusano M, Ino K, Yamada T, Kawamura O, Toki M, Ohwada T, et al. Interobserver and intraobserver variation in endoscopic assessment of GERD using the "Los Angeles" classification. Gastrointest Endosc. 1999; 49: 700-704.
19. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16: 1215.
20. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000; 118: S9-S31.
21. Brosen K, de Morais SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics. 1995; 5: 312-317.
22. Bathum L, Skjelbo E, Mutabingwa TK, Madsen H, Horder M, Brosen K. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol. 1999, 48: 395-401.
23. Goldstein JA, Ishizaki T, Chiba K, De Morais SM, Bell D, Krahn PM, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997; 7: 59-64.
24. Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As, and MDR1/ABCB1. Drug Metab Pharmacokinet. 2004; 19: 83-95.
25. Tassaneeyakul W, Tawalee A, Tassaneeyakul W, Kukongviriyapan V, Blaisdell J, Goldstein JA, et al. Analysis of the CYP2C19 polymorphism in a northeastern Thai population. Pharmacogenetics. 2002, 12: 221-225.
26. Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman-Sundberg M, Eliasson E, et al. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol. 2008; 65: 767-774.
27. Aanen MC, Weusten BL, Numans ME, De Wit NJ, Samsom M, Smout A J. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association. J Clin Gastroenterol. 2008; 42: 441-447.
28. Uno T, Niioka T, Hayakari M, Yasui-Furukori N, Sugawara K, Tateishi T. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations. Eur J Clin Pharmacol. 2007; 63: 143-149.